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EDITORIAL

Cell therapy must be regulated
as medicine
Zihai Li1* and Delong Liu2*
Cell therapy is as old as modern medicine. From blood
transfusion to allogeneic hematopoietic stem cell transplant, cell therapy in the right settings has been proven to
save lives. According to the American Red Cross, a total
of 21 million blood components are transfused each year
in the United States. The Center for International Blood
and Marrow Transplant Research reports more than
50,000 patients worldwide were treated with hematopoietic stem cell transplantation annually.
Unfortunately, cell therapy is also a field that has a
checkered history, which was plagued at one time or
another by superstition, blatant medical malpractice,
and lack of efficacies [1]. At one time blood transfusion
from animals to humans was used as a punishment for
human beings who were deemed evil and cadaver blood
was once thought to be a lucrative commodity. Sadly,
the discovery of blood types and the coagulation system
was also associated with heavy tolls as countless lives
were lost because patients received the “wrong” type or
preparation of blood products. In the midst of these horrors and the devastating impact on human health, blood
medicine pioneers learned the hard lesson that blood
transfusion was vital but was not meant to be done by
amateurs. As we improved our techniques in dealing with
blood products, we were humbly reminded of how little
we actually did understand about the natural law of life as
transfusions of blood products could occasionally serve
as a vehicle to transmit once considered fatal diseases
such as HIV-1 infection and viral hepatitis.
Transfusion medicine has come a long way. It is now a
vital medical specialty with its own well-established practices, principles and guidelines [2, 3]. It has cemented
its place in the foundation of the modern medicine and
blood therapy is now an undeniably effective and often
the only treatment modality for a variety of conditions.
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There are two fundamental roots to cancer: the cancerintrinsic genetic or epigenetic dysregulation of the basic
biology of the cell, and the failure of the cancer-extrinsic
host immune defense mechanism known as immune surveillance to eliminate transformed cells [4]. Immunotherapy is particularly attractive because of its high specificity
and the ability of the immune system to remember cancer cells and mounts a far more efficient immunological
attack later when cancers recur. Not surprisingly, rejuvenating the host immune system for the treatment of cancer has been a dream pursued by generations of scientists.
Presently, with technological advancements and a better
understanding of the immune system, we are finally able
to generate billions of T lymphocytes with defined antigen specificity, natural killer cells, as well as professional
antigen-presenting cells such as dendritic cells [5]. Synthetic immunologists are especially proud of re-directing
T cell antigen-specificity via enforcing the expression of
chimeric antigen receptors and deleting the endogenous
T cell receptor or other regulatory molecules such as program death 1 molecule (PD-1) via gene editing [6]. This
has sparked a tremendous level of interests from the public for the miracle cures that immunotherapy might be
able to deliver. Such a high level of enthusiasm was often
further fueled by press releases and anecdotal reports of
the wonder of killer cells in one form or another in animal studies or in early-phase clinical trials. Unfortunately,
cell therapy for cancer is still at its experimental stage. The
only US Food and Drug Administration (FDA)-approved
cell therapy for cancer (excluding hematopoietic stem
cell transplant), is sipuleucel-T which is indicated for the
treatment of asymptomatic or minimally symptomatic
metastatic castration-resistant (hormone refractory) prostate cancer [7]. Alarmingly, despite warnings from scientists, there is a widespread commercial use of cell therapy
of unclear and unproven efficacy in cancer patients. This
is particularly worrisome in countries where there is no
clear-cut regulatory mechanism governing the practice of
cell-based therapy for desperate cancer patients.
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The exact number of patients who were given unproven
cell therapy was unclear and might never be known, as
the experience of these patients was rarely published
in peer-reviewed international journals. It is less clear
whether or not any of these patients had any meaningful
clinical benefits and worse yet if more harms were done,
medically or economically, to them. In examining some
of the published work, it was often unclear if clinical
studies were conducted under proper supervision by regulatory agencies and local institutional review boards. It
was uncertain if these cellular products such as dendritic
cells, or “cytokine-activated killer cells” that were administered to patients were manufactured under the principles of good manufacturing practice (GMP) with proper
quality controls.
We believe that the application of cell therapy in
human subjects under no clear scientific, ethical and
regulatory monitoring by the pertinent agencies and
policy makers is no better than an act of witchcraft. This
practice is tainting the name of science, scientists or
physicians alike. Worse yet, it puts the vulnerable public
(i.e., the consumers or the patients) in a harm’s way. Lack
of safeguard measures and quality controls to prevent
adverse effects is unfortunately not uncommon. Since
the outcome of the treatment is often not documented
well and communicated to the scientific and medical
community, the public is left without any analyzable scientific data to gain important knowledge to advance the
medicine.
Encouragingly, the medical and research community is acutely aware of the lack of global standards in
the practice of cell therapy and has been calling for
actions. The US FDA continues to release guidance
documents, describing the FDA’s current thinking on
this topic (http://www.fda.gov/BiologicsBloodVaccines/
GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/). There is an ongoing
debate elsewhere on whether cell-based therapy for cancer should be regulated as a medicine or can be merely
regarded as a technology, which of course is under different jurisdictions. However, there is a high hope that
the sweeping scientifically sound and responsible regulatory policy will be put in place in guiding cell therapy
for cancer in both developed and developing countries.
At the same time, unfortunately, many more patients
continue to be treated by the experimental cell therapy
without approval by the proper regulatory authorities;
this include wide spread use of stem cells in non-cancer
conditions [8–10]. For the sake of protecting patients,
it is time now to halt such a practice until the appropriate regulatory policy is put in place. We believe in the
power of science and by no means are calling for stopping proper clinical trials that unleash the wonder of
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immunology or stem cells. We are firmly convinced that
meaningful conclusion cannot be drawn if clinical studies are not conducted correctly and ethically. In the case
of unproven and unregulated commercial practice of cell
therapy for cancer, it runs the risk of causing more harm
than good to our patients, which we collectively have a
moral and professional obligation to oppose.
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